Year |
Citation |
Score |
2017 |
Mihara T, Mensah-Brown K, Sobota R, Lin R, Featherstone R, Siegel SJ. Amygdala activity associated with social choice in mice. Behavioural Brain Research. PMID 28438555 DOI: 10.1016/J.Bbr.2017.04.040 |
0.559 |
|
2015 |
Tatard-Leitman VM, Jutzeler CR, Suh J, Saunders JA, Billingslea EN, Morita S, White R, Featherstone RE, Ray R, Ortinski PI, Banerjee A, Gandal MJ, Lin R, Alexandrescu A, Liang Y, et al. Pyramidal cell selective ablation of N-methyl-D-aspartate receptor 1 causes increase in cellular and network excitability. Biological Psychiatry. 77: 556-68. PMID 25156700 DOI: 10.1016/J.Biopsych.2014.06.026 |
0.599 |
|
2014 |
Billingslea EN, Tatard-Leitman VM, Anguiano J, Jutzeler CR, Suh J, Saunders JA, Morita S, Featherstone RE, Ortinski PI, Gandal MJ, Lin R, Liang Y, Gur RE, Carlson GC, Hahn CG, et al. Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 1603-13. PMID 24525709 DOI: 10.1038/Npp.2014.7 |
0.628 |
|
2013 |
Lin RE, Ambler L, Billingslea EN, Suh J, Batheja S, Tatard-Leitman V, Featherstone RE, Siegel SJ. Electroencephalographic and early communicative abnormalities in Brattleboro rats. Physiological Reports. 1: e00100. PMID 24303172 DOI: 10.1002/Phy2.100 |
0.539 |
|
2013 |
Featherstone RE, M Tatard-Leitman V, Suh JD, Lin R, Lucki I, Siegel SJ. Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expression. Psychopharmacology. 227: 639-49. PMID 23392353 DOI: 10.1007/S00213-013-2997-9 |
0.567 |
|
2013 |
Siegel SJ, Nagy L, Skarsfeldt T, Pierce M, Neill CO, Lin R, Langhamer L, Kordower JH. Ropinirole Implants Reverse MPTP-Induced Parkinsonism in Rhesus Monkeys Pharmacology &Amp; Pharmacy. 4: 1-8. DOI: 10.4236/PP.2013.43A001 |
0.495 |
|
2010 |
Amann LC, Gandal MJ, Lin R, Liang Y, Siegel SJ. In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. Pharmaceutical Research. 27: 1730-7. PMID 20422263 DOI: 10.1007/s11095-010-0152-4 |
0.598 |
|
Show low-probability matches. |